# COVID-19 Vaccine

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/covid-19-vaccine
Canonical HTML page: https://getyourbrief.com/entity/covid-19-vaccine

## Timeline

- **2026-07-20**: Cramer Endorsement & 109% YTD Gain — Motley Fool highlights 109% year-to-date surge and Jim Cramer's comment that Moderna is 'finally investable again'.
- **2026-07-20**: Cramer Endorsement & 109% YTD Gain — Motley Fool highlights 109% year-to-date surge and Jim Cramer's comment that Moderna is 'finally investable again'.
- **2026-06**: Quarterly Update — Moderna reports a 26% reduction in operating expenses, reiterates up to 10% revenue growth target for 2026.
- **2026-06**: Quarterly Update — Moderna reports a 26% reduction in operating expenses, reiterates up to 10% revenue growth target for 2026.
- **2022**: Post-Pandemic Decline — Demand for COVID vaccines wanes, RSV sales miss expectations, and CMV candidate fails; stock loses over 80% from peak.
- **2022**: Post-Pandemic Decline — Demand for COVID vaccines wanes, RSV sales miss expectations, and CMV candidate fails; stock loses over 80% from peak.
- **2020**: COVID Vaccine Success — Moderna's COVID-19 vaccine drives record revenue; stock surges over 2,000% from early 2020 through August 2021.
- **2020**: COVID Vaccine Success — Moderna's COVID-19 vaccine drives record revenue; stock surges over 2,000% from early 2020 through August 2021.

## Recent coverage (4 stories, network-wide)

### Moderna's 109% Stock Surge: What It Means for Global Health and mRNA Vaccines
2026-07-21 00:07:56 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 2

Moderna’s financial rebound could accelerate the deployment of mRNA technology for RSV, flu, and future pandemics, enhancing public health resilience.
Full story: https://gethealthbrief.com/story/moderna-health-mrna-impact-109

### Moderna Up 109% YTD: Cramer Calls It Investable—Is It a Buy on the Dip?
2026-07-21 00:07:49 · Sector: finance · Sentiment: Positive · Impact: 6/10 · Sources: 2

Jim Cramer’s bullish pivot comes as Moderna stock pulls back from its 109% YTD gain, raising the question: does the dip offer a compelling entry for investors?
Full story: https://getfinancebrief.com/story/moderna-finance-cramer-dip-buying-109

### After 109% Rally, Moderna’s Pipeline Progress and 10% Revenue Goal
2026-07-21 00:07:40 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2

Moderna’s cost cuts and pipeline milestones, from RSV commercialization to latent virus programs, are restoring biotech investor confidence despite past setbacks.
Full story: https://getbiobrief.com/story/moderna-bio-pipeline-revival-109

### Large Study Confirms Maternal COVID-19 Vaccination Protects Infants Post-Birth
2026-03-25 16:27:34 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 14

A comprehensive multi-site study has confirmed that COVID-19 vaccination during pregnancy significantly reduces the risk of hospitalization for infants in their first six months of life. The findings provide robust evidence for the benefits of transplacental antibody transfer in protecting neonates who are not yet eligible for vaccination.
Full story: https://gethealthbrief.com/story/maternal-covid-vaccination-infant-protection-study

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.